Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MRI waiting period eliminated for Taxus:

This article was originally published in Clinica

Executive Summary

Boston Scientific has received for its drug-eluting stent (DES), Taxus, a new clearance from the US FDA that allows MRI to be performed on patients immediately following the device's implantation. Taxus is the first DES to be approved for immediate MRI exams, the firm claimed, adding that the approval also applied to the bare-metal version of the stent. Coronary stent recipients can now avoid the two-month waiting period previously required before undergoing MRI during the most critical stage of their recovery, said the firm. In a separate announcement, Boston said it has become the first company to offer a full range of DES sizes, with the launch of three large sizes of Taxus (for vessel sizes of between 4-5mm). The new sizes are set for immediate launch in Europe and in other countries outside the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054752

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel